Posted On: 10/26/2016 1:10:31 PM
Post# of 72447
Sounds like management decided to submit the SPA response to the FDA. Do you read the same?
Quote:
Communications also continue with the FDA on the Company’s Special Protocol Assessment (SPA) request for its planned Phase 3 clinical trial of single-dose Brilacidin in the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria.
(1)
(0)
